Murat Yildiz
Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study
Yildiz M, Tettenborn B, Radue E, Bendfeldt K, Borgwardt S. Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study. Clin Neurol Neurosurg 2014; 127:54-8.
14.10.2014Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study
14.10.2014Clin Neurol Neurosurg 2014; 127:54-8
Yildiz Murat, Tettenborn Barbara, Radue Ernst-Wilhelm, Bendfeldt Kerstin, Borgwardt Stefan
Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients
Yildiz M, Tettenborn B, Borgwardt S. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients. Clin Neurol Neurosurg 2012; 115:902-3.
27.09.2012Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients
27.09.2012Clin Neurol Neurosurg 2012; 115:902-3
Yildiz Murat, Tettenborn Barbara, Borgwardt Stefan
Contact dermatitis induced by glatiramer acetate
Haltmeier S, Yildiz M, Müller S, Anliker M, Heinzerling L. Contact dermatitis induced by glatiramer acetate. Mult Scler 2011; 17:1390-2.
05.07.2011Contact dermatitis induced by glatiramer acetate
05.07.2011Mult Scler 2011; 17:1390-2
Haltmeier S, Yildiz Murat, Müller S, Anliker Mark, Heinzerling L
Vitamin D levels in Swiss multiple sclerosis patients
Tettenborn B, Yildiz M, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. Swiss Med Wkly 2011
03.05.2011Vitamin D levels in Swiss multiple sclerosis patients
03.05.2011Swiss Med Wkly 2011
Tettenborn Barbara, Yildiz Murat, Putzki Norman
Vitamin D levels in Swiss multiple sclerosis patients
Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. Swiss Med Wkly 2011; 141:w13192.
03.05.2011Vitamin D levels in Swiss multiple sclerosis patients
03.05.2011Swiss Med Wkly 2011; 141:w13192
Yildiz Murat, Tettenborn Barbara, Putzki Norman
Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up
Yildiz M, Müller S, Vehoff J, Tettenborn B (2011). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up.
09.04.2011Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up
09.04.2011AAN
Yildiz Murat, Müller Stefanie, Vehoff Jochen, Tettenborn Barbara
Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate
Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol 2011; 65:231-2.
31.03.2011Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate
31.03.2011Eur Neurol 2011; 65:231-2
Yildiz Murat, Tettenborn Barbara, Putzki Norman
Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate
Yildiz M, Tettenborn B, Putzki N (2010). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate.
13.10.2010Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate
13.10.2010ECTRIMS
Yildiz Murat, Tettenborn Barbara, Putzki Norman
Natalizumab and beyond
Yildiz M, Tettenborn B, Putzki N. Natalizumab and beyond. Eur Neurol 2010; 64:236-40.
04.09.2010Natalizumab and beyond
04.09.2010Eur Neurol 2010; 64:236-40
Yildiz Murat, Tettenborn Barbara, Putzki Norman